Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739344 | 0.77 | ALDH1A1 (0.44) | FOLH1CYP19A1CYP1A1GAACYP1A2 | |
| SCHEMBL1968712 | 0.73 | TSHR (0.56) | FOLH1CYP19A1CYP1A1NPC1TSHR | |
| SCHEMBL28807834 | 0.72 | FOLH1 (0.39) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL28317337 | 0.71 | FOLH1 (0.35) | FOLH1CYP19A1CYP1A1TSHR | |
| SCHEMBL9284133 | 0.70 | CYP19A1 (0.58) | CYP19A1CYP1A1KMT2A | |
| SCHEMBL18377936 | 0.70 | NPC1 (0.42) | NPC1POLBGAANPSR1CYP1A2 | |
| SCHEMBL30724678 | 0.69 | — | — | |
| SCHEMBL6714332 | 0.69 | POLB (0.37) | NPC1POLBGAANPSR1CYP1A2 | |
| SCHEMBL10643045 | 0.69 | TBXAS1 (0.48) | — | |
| SCHEMBL15825610 | 0.69 | NPC1 (0.35) | NPC1POLBGAANPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905287-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL (GB) | 2024-02-20 | — | — | US | claimed |
| US-11667638-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL | 2023-06-06 | — | — | US | claimed |
| EP-3500572-B1 | CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION | UNIV BRISTOL (GB) | 2022-10-26 | — | — | EP | claimed |
| US-20200172544-A1 | COMPOUNDS | THE UNIVERSITY OF BRISTOL (GB) | 2020-06-04 | — | — | US | claimed |
| WO-2024048615-A1 | METHOD FOR PRODUCING QUINOXALINE DERIVATIVE | 協和キリン株式会社 | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667638-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | FOLH1 1072/4885CYP19A1 1943/4885CYP1A1 485/4885 |
| US-20200172544-A1 | COMPOUNDS | CES2, CYCS, CHKB | FOLH1 2044/4885CYP19A1 1857/4885CYP1A1 356/4885 |
| US-11905287-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | FOLH1 1072/4885CYP19A1 1943/4885CYP1A1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.